During the corresponding time, Prelude Therapeutics Inc sequentially revenue grew by 24.54 %. While revenue at the Prelude Therapeutics Inc's corporate clients
Prelude Therapeutics Inc: A New Chapter in Targeted Cancer Therapies Amid Financial Challenges and Promising Preclinical Data Prelude Therapeutics Inc, a biotechnology company dedicated to transforming the treatment landscape for patients with cancer, recently announced the presentation of preclinical data on PRT3789 at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PRT3789 is Prelude s first-in-class, highly selective SMARCA2 degrader that is currently in early clinical development. This innovative therapeutic strategy aims to exploit the degradation of specific proteins involved in tumorigenesis, indicating a move toward more personalized cancer treatment modalities.The presentati...
Prelude Therapeutics, a leader in developing targeted therapies for various malignancies, has reported encouraging preliminary results from ongoing clinical trials involving two of its key investigational compounds, PRT2527 and PRT3789. These compounds aim to address unmet medical needs in relapsed/refractory lymphoid malignancies and SMARCA4-mutated solid tumors, respectively. The company s strategic vision for 2024 further underlines its commitment to advancing these therapies toward potential proof-of-concept data. Targeted therapy continues to evolve as a vital approach in oncology, offering new hope for patients with challenging malignancies. Prelude Therapeutics recent disclosures regarding the cl...
Prelude Therapeutics Inc. is poised to make a significant impact in the field of oncology with its novel therapeutic candidate, PRT3789, which is set to be presented at the prestigious 36th EORTC-NCI-AACR Symposium on October 24, 2024. This symposium, an essential gathering in cancer research, will host a plenary session where Prelude will unveil findings regarding PRT3789, a highly-selective degrader targeting SMARCA2 in patients with advanced solid tumors harboring SMARCA4 mutations.SMARCA2, a member of the SWI/SNF chromatin remodeling complex, has emerged as a critical player in the progression of certain cancers. The ability of PRT3789 to selectively degrade SMARCA2 represents a promising new avenue for ...
Prelude Therapeutics Inc. has recently garnered attention within the pharmaceutical sector due to their innovative therapeutic approach targeting cancer through the degradation of the SMARCA2 protein. Notably, their investigational drug, PRT3789, demonstrated promising initial clinical activity and a favorable safety profile in its Phase 1 trial, especially among patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. While these early findings signal potential breakthroughs in treatment, Prelude Therapeutics is concurrently facing challenges in market performance that merit discussion. Promising Clinical ResultsIn the early stages of the PRT3789 monotherapy dose escalation tr...
The American Association for Cancer Research (AACR) held its annual meeting in 2024, where an exciting breakthrough in cancer research was unveiled by Prelude Therapeutics Inc. The event provided a platform to highlight the continued strength of Prelude s discovery engine, with special focus on their novel orally available SMARCA2 degrader, PRT7732. This article aims to delve into the findings presented at the event and discuss the potential significance of PRT7732 as a monotherapy and in combination with chemotherapy for the treatment of cancer.SMARCA2 Degradation Strategy:SMARCA2, a key protein involved in chromatin remodeling and gene regulation, has been identified as a potential target for cancer therap...
Sources:
Prelude Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Prelude Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Prelude Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
